Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives us an update on the analysis of the UK Myeloma XI trial (NCT01554852) by molecular risk from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. This trial investigated the efficacy of the quadruplet induction regimen of carfilzomib, cyclophosphamide, lenalidomide and dexamethasone for newly diagnosed multiple myeloma patients.